Conversion ratio of tacrolimus switching from intravenous infusion to oral administration after lung transplantation
Conversion ratio of tacrolimus switching from intravenous infusion to oral administration after lung transplantation
复制标题
肺移植术后他克莫司静脉输注转口服的转化率
DOI:
10.21037/jtd-20-1191
复制
发表时间:
2020-07
影响因子:
2.5
通讯作者:
Liu Xiao-Qing
中科院分区:
文献类型:
--
作者:
Yang Chun;Xi Yin;Chen Wen-Ying;Sang Lin;Liu Dong-Dong;Zhang Rong;Chen Si-Bei;Zhang Jie;Pan Jie-Yi;Xv Yong-Hao;Nong Lin-Bo;Li Yi-Min;Liu Xiao-Qing
Background To investigate the conversion ratio of tacrolimus switching from intravenous infusion to oral administration in patients after lung transplantation. Methods We retrospectively recruited patients received lung transplantation in the First Affiliated Hospital of Guangzhou Medical Hospital from January 2015 to June 2019. The blood concentration of tacrolimus administrated through intravenous infusion and oral administration were collected. The blood concentration, concentration/dose ratio (C/D), and (C/Dpo)/(C/Div) ratio were analyzed to explore the conversion ratio of tacrolimus switching from intravenous infusion to oral administration, as combined medication of tacrolimus and caspofungin were used. Results The concentration of intravenously administered tacrolimus was significantly higher than that of oral administration; the C/D ratio of intravenously administrated tacrolimus (C/Div) was significantly higher than that of the oral administration (C/Dpo). There was a significant correlation between C/Dpo and C/Div (R2 =0.774, P<0.001). The conversion ratio of tacrolimus from intravenous administration to oral administration was 1:7.4, as combined medication of tacrolimus and caspofungin were used. Conclusions The conversion ratio of tacrolimus switching from intravenous to oral administration is 1:7.4 in the combination treatment of tacrolimus and caspofungin after lung transplantation.
登录
查看更多内容
DOI:
10.1002/14651858.cd005161.pub2
发表时间:
2006-10
期刊:
The Cochrane database of systematic reviews
影响因子:
--
作者:
E. Haddad;Vivian Charles McAlister;E. Renouf;R. Malthaner;M. Kjaer;L. Gluud
通讯作者:
E. Haddad;Vivian Charles McAlister;E. Renouf;R. Malthaner;M. Kjaer;L. Gluud
DOI:
10.1016/j.jinf.2004.05.011
发表时间:
2005-04
期刊:
The Journal of infection
影响因子:
--
作者:
N. Kartsonis;A. Saah;C. Joy Lipka;Arlene F. Taylor;C. Sable
通讯作者:
N. Kartsonis;A. Saah;C. Joy Lipka;Arlene F. Taylor;C. Sable
影响因子:
3.3
作者:
KINO, T;HATANAKA, H;OCHIAI, T
通讯作者:
OCHIAI, T
DOI:
10.1592/phco.21.13.1107.34613
发表时间:
2001-09
期刊:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
影响因子:
--
作者:
J. Cannon;K. Garey;L. Danziger
通讯作者:
J. Cannon;K. Garey;L. Danziger
影响因子:
8.9
作者:
Kaczmarek, Ingo;Zaruba, Marc-Michael;Meiser, Bruno
通讯作者:
Meiser, Bruno